A bedside medication framework for fluid removal, sodium emergencies, potassium shifting/stabilization, acid–base rescue and electrolyte replacement—always distinguishing temporary physiologic manipulation from definitive solute removal or disease treatment.
Separate membrane stabilization, intracellular potassium shift and definitive potassium removal.
Use 3% hypertonic saline for symptomatic hyponatremia with explicit correction limits and overcorrection rescue planning.
Use desmopressin strategically in central DI and in selected hyponatremia overcorrection prevention/rescue.
Treat loop-diuretic resistance as a pharmacology problem before declaring diuretics ineffective.
Use bicarbonate and acetazolamide only when the acid–base phenotype provides a plausible target.
The table below is a selection framework. Open the individual monograph for exact dosing, preparation, renal/CRRT/IHD adjustment, interactions and evidence traceability.
ICU role: Loop diuretic for congestion/volume overload and selected kaliuresis when kidneys respond.
Monitor: Urine output, weight/fluid balance, BP, creatinine, Na/K/Mg.
ICU role: Carbonic anhydrase inhibitor causing bicarbonaturia and proximal natriuresis.
Monitor: Bicarbonate/pH, K/Na, renal function, urine output.
ICU role: Hypertonic sodium therapy for severe symptomatic hyponatremia and selected intracranial hypertension.
Monitor: Serum sodium frequently, symptoms, urine output, chloride/volume status.
ICU role: V2 agonist for central DI and selected prevention/rescue of overly rapid water diuresis during hyponatremia correction.
Monitor: Na, urine output/osmolality, fluid balance.
ICU role: Alkali and sodium-channel-antagonism therapy with indication-specific roles.
Monitor: pH/HCO3, Na/K/Ca, ventilation, volume status, ECG when toxicology indication.
ICU role: Cardiac membrane stabilization in severe hyperkalemia and calcium replacement.
Monitor: ECG, ionized calcium, IV access/extravasation.
ICU role: Magnesium replacement plus disease-specific therapy for torsades and eclampsia.
Monitor: Renal function, reflexes/respiration in high exposure, Mg level when indicated.
ICU role: Temporizing intracellular potassium shift and primary therapy for DKA/HHS under different dosing protocols.
Monitor: Glucose serially, K, ECG, definitive elimination plan.
| Agent | ICU role | Why I choose it | Why I hesitate | What I monitor |
|---|---|---|---|---|
| Furosemide Loop Diuretic — NKCC2 Inhibitor | Loop diuretic for congestion/volume overload and selected kaliuresis when kidneys respond. | ✓ Use when the patient has excess extracellular volume and residual tubular delivery/function. | ✕ Diuresis treats fluid overload, not intrinsic AKI itself; underdosing in severe congestion/renal dysfunction can mimic resistance. | Urine output, weight/fluid balance, BP, creatinine, Na/K/Mg. |
| Acetazolamide Carbonic Anhydrase Inhibitor | Carbonic anhydrase inhibitor causing bicarbonaturia and proximal natriuresis. | ✓ Useful in selected metabolic alkalosis with volume overload and as sequential nephron blockade. | ✕ Can worsen metabolic acidosis/hypokalemia and is not a universal 'diuretic booster'. | Bicarbonate/pH, K/Na, renal function, urine output. |
| Hypertonic Saline (3%) Hyperosmolar Agent / Concentrated Electrolyte Solution | Hypertonic sodium therapy for severe symptomatic hyponatremia and selected intracranial hypertension. | ✓ Rapid small sodium rise for severe neurologic hyponatremia symptoms; also hyperosmolar neuro rescue under separate protocols. | ✕ Overcorrection risks osmotic demyelination; indication/endpoints differ from ICP use. | Serum sodium frequently, symptoms, urine output, chloride/volume status. |
| Desmopressin Synthetic Vasopressin V2 Receptor Agonist / Hemostatic Peptide | V2 agonist for central DI and selected prevention/rescue of overly rapid water diuresis during hyponatremia correction. | ✓ Useful when uncontrolled aquaresis threatens sodium overcorrection or proven central DI is causing hypernatremic polyuria. | ✕ Can cause water retention/hyponatremia; do not give reflexively to every polyuric patient. | Na, urine output/osmolality, fluid balance. |
| Sodium Bicarbonate Alkalinizing Agent / Buffer | Alkali and sodium-channel-antagonism therapy with indication-specific roles. | ✓ Core therapy for TCA/sodium-channel blocker cardiotoxicity; selected severe acidemia/hyperkalemia contexts may benefit. | ✕ Not routine treatment for all lactic acidosis; sodium/volume load, alkalemia, hypocalcemia and CO2 generation matter. | pH/HCO3, Na/K/Ca, ventilation, volume status, ECG when toxicology indication. |
| Calcium Gluconate Electrolyte / Cardiac Membrane Stabilizer | Cardiac membrane stabilization in severe hyperkalemia and calcium replacement. | ✓ Immediate ECG protection in hyperkalemia with concerning changes; also treats symptomatic hypocalcemia. | ✕ Does not lower serum potassium; repeat based on ECG response and context. | ECG, ionized calcium, IV access/extravasation. |
| Magnesium Sulfate Electrolyte / Multi-Mechanism Membrane & Neuromuscular Modulator | Magnesium replacement plus disease-specific therapy for torsades and eclampsia. | ✓ Torsades/long-QT ventricular arrhythmia, eclampsia, and clinically important hypomagnesemia. | ✕ Renal failure increases toxicity; not every arrhythmia improves with magnesium. | Renal function, reflexes/respiration in high exposure, Mg level when indicated. |
| Regular Insulin (IV) Rapid-Onset IV Insulin — Endogenous Peptide Hormone | Temporizing intracellular potassium shift and primary therapy for DKA/HHS under different dosing protocols. | ✓ Rapid reliable K shift in severe hyperkalemia with dextrose as appropriate. | ✕ Does not remove total body potassium; delayed hypoglycemia is common in renal failure. | Glucose serially, K, ECG, definitive elimination plan. |
Why: Stabilization, shift and removal are three separate therapeutic jobs.
Why: The emergency goal is symptom control, not normal sodium; overcorrection causes neurologic injury.
Why: Once ADH suppression triggers brisk water loss, sodium can rise much faster than planned.
Why: Diuretic resistance often reflects dose, delivery, distal adaptation and congestion physiology.
Why: Alkali has specific indications and tradeoffs; correcting the cause is primary.
Recognition becomes selection, then organ-failure adjustment, competing physiology and senior-level prioritization.
K 7.1 mmol/L with wide QRS in dialysis-dependent ESRD.
Calcium stabilizes the myocardium; insulin/dextrose shifts potassium intracellularly; dialysis removes potassium. Use all needed components rather than expecting one drug to do all three jobs.
Na 112 mmol/L with a generalized seizure and no obvious chronicity.
Give protocolized 3% hypertonic saline bolus therapy immediately, aiming for a small early rise sufficient to control severe symptoms, then monitor sodium closely and avoid overcorrection.
After saline, Na rises from 108 to 116 mmol/L in 6 h and urine output suddenly becomes 500 mL/h of dilute urine.
Recognize impending overcorrection from water diuresis. Stop ongoing correction drivers and use a DDAVP/electrolyte-free water strategy according to high-risk correction limits and local protocol.
Severe heart failure, edema, alkalosis, CrCl 28; low-dose furosemide produces little urine.
Do not label the kidney 'diuretic resistant' after an inadequate loop exposure. Optimize loop dosing/route, assess congestion and chloride/K status, then consider sequential nephron blockade such as acetazolamide when alkalosis/volume phenotype fits.
Septic shock, lactate 8 mmol/L, pH 7.24, PaCO2 appropriate, K 4.3 and improving perfusion after source control/vasopressors. A team member requests bicarbonate to normalize HCO3.
Continue cause-directed resuscitation and reassessment. Sodium bicarbonate is not indicated merely because lactate/HCO3 are abnormal; use it for specific acidemia/toxicology/hyperkalemia contexts where benefit plausibly outweighs sodium/CO2/ionized-calcium effects.
Loop diuretic used for acute decongestion when clinically important congestion/volume overload is present. In acute pulmonary edema, whether diuresis is the immediate priority depends on the hemodynamic phenotype; markedly hypert…
Proximal-tubule diuretic that inhibits carbonic anhydrase, producing bicarbonaturia and mild natriuresis — an ADVOR-trial-supported adjunct to loop diuretics in selected adults hospitalized with acute decompensated heart failure …
High-tonicity sodium solution (513 mEq/L Na⁺ and Cl⁻, 1026 mOsm/L) used for rapid osmotic intracranial pressure reduction in cerebral herniation and for emergent correction of severe symptomatic hyponatremia.
Synthetic vasopressin analog with strong V2 antidiuretic activity and endothelial release of von Willebrand factor/factor VIII. It is labeled for central diabetes insipidus and selected bleeding disorders; ICU use for uremic blee…
A deliberately narrow-role buffer reserved for severe metabolic acidosis with concurrent AKI, sodium-channel-blocker toxicity, and select hyperkalemia with significant concurrent acidemia — explicitly NOT a routine therapy for la…
First-line cardiac membrane stabilizer for hyperkalemic ECG changes and definitive replacement therapy for symptomatic hypocalcemia — the single most important teaching point is that it stabilizes the myocardium without changing …
Spans four genuinely distinct ICU indications — torsades de pointes, adjunctive severe asthma therapy, eclampsia/severe preeclampsia, and simple hypomagnesemia repletion — each with its own mechanism-relevant dosing; no single do…
IV regular insulin is used for distinct ICU purposes — DKA, HHS/mixed hyperglycemic crisis, temporizing potassium shift in hyperkalemia, and general ICU glycemic control — each with different dosing and endpoints; insulin SHIFTS …
This Masterclass teaches selection and reasoning. Exact dosing, concentration, infusion preparation, renal/hepatic/RRT adjustment and monitoring must be checked in the linked medication monograph and the institution's current formulary/protocol. Local resistance patterns and regulatory drug availability can change faster than a static teaching page.